WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
Meet the new 'dynamic duo'! Anne and Sophie pair up to share the royal burdenDoctor reveals shocking theory behind why you suddenly need to use the toilet during shopping tripsIn Charles and William's absence, the littleChina news: Solomon Islands strikes $95 million Huawei internet dealQueen Maxima of the Netherlands wows in blue as she meets students in AmsterdamMeghan Markle continues to wear neutral clothing four years on from the Sussex's 'freedom flight'King Charles's call for all ableNATASHA LIVINGSTONE: StraightMeet the new 'dynamic duo'! Anne and Sophie pair up to share the royal burdenDanish queens don't get to be crowned. But when Margrethe steps down this weekend, her daughter
3.6476s , 6499.03125 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,Stellar Station news portal